MARK BLOCKER: Open Payments
NPI 1104321397 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,821 in 110 payments from 16 companies in 2025. Trend: 2023 $2,024 · 2024 $2,241 · 2025 $1,821
Food & beverage: $1,821
| Company | Payments | Amount |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 16 | $240 |
| Noven Therapeutics, LLC | 22 | $217 |
| Supernus Pharmaceuticals, Inc. | 7 | $167 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $166 |
| Vanda Pharmaceuticals Inc. | 9 | $151 |
| ABBVIE INC. | 10 | $151 |
| Tris Pharma Inc | 9 | $144 |
| Corium, LLC | 5 | $102 |
| Neurocrine BioSciences, Inc. | 4 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
Products named: Jornay PM, Xelstrym, Qelbree, CAPLYTA, FANAPT, VRAYLAR, Dyanavel XR, REXULTI.
Industry payments across GA — which companies pay providers there.
